Distribution of the CKD273 scoring in patients before and after treatment with empagliflozin.

<p>Distribution of the CKD273 scoring in patients before and after treatment with empagliflozin.</p

Box-Whisker blots of the scoring representing the proteome changes induced as a result of empagliflozin treatment.

<p>The clear separation of the groups prior and after treatment is evident. However, when applying this classifier to a cohort of CKD patients and controls, the controls score slightly, yet significantly (p<0.01) higher (indicative of empagliflozin treatment) than the CKD patients.</p

Distribution of the 107 peptides found associated with empagliflozin treatment in the cohort investigated.

<p>Each peptide is displayed based on the mass (in kDa, using a logarithmic scale) and migration time (in minutes). The average relative abundance is represented by the peak intensity. To depict also the lower abundant peptides, the same 107 peptides with abundance magnified 10-fold are shown on the right. Panel A shows the distribution of the 107 peptides before treatment, panel B depicts the distribution after treatment. To ease assessment of changes, the data from patients before and after treatment were superimposed in panel C, peaks were labeled red before EMPA treatment and green after EMPA treatment, the yellow fraction of the peak indicates the overlap in abundance between before and after treatment.</p

Lists the 46 peptides significantly different prior to and after treatment with empagliflozin.

<p>Lists the 46 peptides significantly different prior to and after treatment with empagliflozin.</p

Additional file 2: Table S2. of Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

Multivariate analysis on the determinants of the plasma aldosterone concentration during placebo and during losartan treatment. In this table we illustrate the association between creatinine clearance and the plasma aldosterone concentration during placebo and losartan treatment, while adjusting for age and gender. (DOCX 13 kb